Maternal Deworming Research Study (MADRES) protocol: a double-blind, placebo-controlled randomised trial to determine the effectiveness of deworming in the immediate postpartum period

BMJ Open. 2015 Jun 17;5(6):e008560. doi: 10.1136/bmjopen-2015-008560.


Introduction: Soil-transmitted helminth infections are endemic in 114 countries worldwide, and cause the highest burden of disease among all neglected tropical diseases. The WHO includes women of reproductive age as a high-risk group for infection. The primary consequence of infection in this population is anaemia. During lactation, anaemia may contribute to reduced quality and quantity of milk, decreasing the duration of exclusive breastfeeding and lowering the age at weaning. To date, no study has investigated the effects of maternal postpartum deworming on infant or maternal health outcomes.

Methods and analysis: A single-centre, parallel, double-blind, randomised, placebo-controlled trial will be carried out in Iquitos, Peru, to assess the effectiveness of integrating single-dose 400 mg albendazole into routine maternal postpartum care. A total of 1010 mother-infant pairs will be randomised to either the intervention or control arm, following inhospital delivery and prior to discharge. Participants will be visited in their homes at 1, 6, 12 and 24 months following delivery for outcome ascertainment. The primary outcome is infant mean weight gain between birth and 6 months of age. Secondary outcomes include other infant growth indicators and morbidity, maternal soil-transmitted helminth infection and intensity, anaemia, fatigue, and breastfeeding practices. All statistical analyses will be performed on an intention-to-treat basis.

Ethics and dissemination: Research ethics board approval has been obtained from the McGill University Health Centre (Canada), the Asociación Civil Impacta Salud y Educación (Peru) and the Instituto Nacional de Salud (Peru). A data safety and monitoring committee is in place to oversee study progression and evaluate adverse events. The results of the analyses will be published in peer-reviewed journals, and presented at national and international conferences.

Trial registration number: NCT01748929.

Keywords: PARASITOLOGY; albendazole; helminthiasis; intervention study; postpartum; randomised controlled trials.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Albendazole / administration & dosage*
  • Anthelmintics / administration & dosage*
  • Breast Feeding
  • Cost-Benefit Analysis
  • Double-Blind Method
  • Female
  • Helminthiasis / complications
  • Helminthiasis / drug therapy
  • Helminthiasis / prevention & control*
  • Humans
  • Infant
  • Infant Nutrition Disorders / prevention & control*
  • Infant Nutritional Physiological Phenomena
  • Infant, Newborn
  • Lactation
  • Male
  • Maternal Nutritional Physiological Phenomena
  • Mothers*
  • Peru / epidemiology
  • Postpartum Period
  • Pregnancy
  • Soil / parasitology
  • Treatment Outcome


  • Anthelmintics
  • Soil
  • Albendazole

Associated data